|
"The doctor asked me if I knew what the results meant. I said yes, this was the most dangerous type of cancer. Then he told me I had only three months to live."
LONG LASTING SURVIVAL
After metastatic cancer
In 2012, Katalin went to the doctor with unusual weakness and shortness of breath. She had never smoked, but after a few visits, she was diagnosed with lung cancer that had spread to her lymph nodes and brain. The doctor gave Katalin only three months to live, which triggered her survival instinct. “The first step is to find a treatment you can trust,” Katalin says.
Katalin was referred to the National Cancer Institute, which - with Katalin's consent - sent her results to the molecular diagnostics lab of Oncompass Medicine (the predecessor of Genomate). This was where her difficult but successful journey to recovery began. Katalin went into the fight with unwavering faith and confidence.
The OCM team identified the genetic mutation that caused Katalin’s disease. At that time, experts hand-picked the most appropriate personalized therapy, which was part of a clinical trial held in Spain, making it the only option available globally.
Throughout her cancer journey, the OCM team has been by Katalin's side, providing vital support in coordinating her treatment.
And as a result, “It’s been a decade since I’ve been symptom-free. A lot has happened since my diagnosis, and perhaps the most rewarding aspect is that I’ve welcomed three grandchildren into my life. I can now be actively involved in the lives of five children as a loving grandmother,” Katalin shares.
THE FOUNDATION OF SUCCESS
This success was possible thanks to Oncompass Medicine’s (the predecessor of today’s Genomate) diagnostic technology and targeted drugs. Throughout its twenty-year journey, Oncompass Medicine’s mission has remained the same: to bring innovative therapies to as many patients as possible, years ahead of schedule.
For example, the drug that proved effective in Spain in 2013 in Katalin's case was only registered and made available to cancer patients in Hungary for specific indications in 2019.
Dr. István Peták, Chief Scientific Officer of Oncompass Medicine, added: " We understand that the road to recovery is arduous and painful for every cancer patient. The past twenty years have been a constant struggle for Oncompass. However, every moment of perseverance has been worth it as we have achieved success in many cancer cases. Over the past two decades, tens of thousands of patients from almost every corner of the world have placed their trust in Oncompass Medicine. We are confident that this number will continue to increase in the next twenty years. With a unified global effort, we aim to defeat and end cancer from this current era."
To realize this ambition, Oncompass Medicine, as a digital healthcare company, plans to expand its support for cancer patients in the future through new platforms developed by itself.
From molecular diagnostics to follow-up care, OCM aims to create a global digital safety net for prevention-focused patients and those battling cancer. This network will provide the highest quality professional support and supervision, accessible to everyone, even when not physically present, providing access to the most advanced diagnostic and treatment planning tools based on the latest scientific advances.